この製品に関するご照会・お問合せはこちら

Immunoassay of Antibody-Drug Conjugates (ADCs)

—Pharmacokinetic (PK) Characterization of ADCs

As a leader in the development of antibody-drug conjugates (ADCs), Creative Diagnostics has developed a portfolio of ELISA kits for the quantitative detection of conjugate antibodies targeting commonly encountered payloads such as MMAE, SN38 and DM1. These kits provide highly sensitive monitoring of conjugate antibody concentrations in serum and plasma, with high reproducibility and inter-batch consistency of test results. They are excellent tools for PK studies of ADCs.

For conjugated antibody quantification, the capture reagent is the antibody targeting the cytotoxic drug. After capturing the conjugated antibody, the amount is quantified using biotin antigen or anti-CDR mAb. 

Fig.1 Principle of Conjugated Antibody Quantitative Detection

Key Features:

• For PK assay of ADCs in pre-clinical/clinical studies (for research use only)
• No cross-reactivity with other ADC analogs
• Lot-to-lot consistency
• High specificity/sensitivity/stability
• Passed stability test at 37°C for 7 days

Performance Characteristics

The Intact MMAE ADC ELISA Kit (DEIABL314) developed by Creative Diagnostics has demonstrated excellent validation data as shown in the table below:

Precision

Product List